查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425115

动物生物技术市场 - 2024 年至 2029 年预测

Animal biotechnology Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

动物生物技术市场预计在预测期内复合年增长率为 6.28%。

动物生物技术已经生产出具有更高生长速度、抗病能力以及合成治疗性蛋白质的能力的动物。随着动物基因组定序、基因表现和动物细胞代谢谱的最新进展，动物生物技术也取得了进展。基因组编辑技术（包括 TALENS、CRISPR-Cas 和锌指核酸酶）的最新进展，为快速改变动物的遗传组成提供了新的可能性，从而改善动物的健康和福利、农业生产力和抗病能力。

动物生物技术市场驱动因素

对基因工程治疗性蛋白质的需求不断增长，以提高抗病能力、在癌症治疗中的应用以及增加动物的预防保健，是动物生物技术市场的一些主要成长要素。对农业、肉类生产和动物源性产品中使用动物的需求不断增加，社会对动物健康和福利的关注不断增加，动物在人类药物生产中的作用不断扩大，以及畜牧业的增加，所有这些因素都促成了扩张生物技术市场。

狗的肥胖、发炎和癌症盛行率增加

狗最常见的营养问题是肥胖，而最近的肥胖流行是动物生物技术市场扩张的主要驱动力。在一些国家，肥胖在狗中很常见。慢性恶性度发炎是肥胖对健康产生许多负面影响的常见解释。这已被普遍认可和接受，多项研究表明肥胖与多种恶性及相关影响的风险增加之间存在关联。这些解释极为重要，因为与肥胖一样，近年来狗的癌症发生率增加，并且是这些动物死亡的重要原因。

政府加大力度

根据「同一个健康」方针，为了提高印度对潜在动物流行病的准备和应对能力，印度渔业、畜牧业和酪农部长帕肖坦·鲁帕拉(Shri Parshottam Rupala) 宣布，动物流行病防范倡议和世界银行宣布动物卫生系统支持资助一个健康。该倡议的重点是对动物和人类都危险的通用感染疾病，旨在提高印度对动物流行病的准备和应对能力。该倡议将透过社区参与增加农民的知识，同时改善兽医服务和基础设施、疾病监测能力、早期发现和应对以及动物卫生专业人员的能力。此外，2021年1月，加拿大政府和安大略省政府将透过加拿大农业合作伙伴关係提供高达400万加元的资金，以确保农民在需要时能够获得兽医服务。

疫苗需求增加

动物生物技术市场疫苗成长的主要原因是动物疾病盛行率上升。这些疾病透过摄取受污染的食物或水、透过与病人或动物的密切接触或透过其他自然方式从动物自然传播给人类。此外，将于 2023 年 6 月推出 NANDI（新药和新免疫系统核准），这表明 DAHD 在实施动物流行病防范倡议 (APPI) 中指示的治疗方法方面正在取得进展。此外，2023年7月，支持兽用疫苗的使用和开发的疫苗评估和抗菌替代品中心（CVEAA）在堪萨斯州立大学兽医学院正式成立。

在北美，动物生物技术市场预计将稳定成长。

医疗保健计划的存在和对动物健康促进的持续努力预计将增加该地区动物生物技术市场的成长潜力。此外，该地区强劲的研发投资预计将加速北美动物生物技术市场的扩张。例如，2023年5月，美国国家标准与技术研究院（NIST）和美国食品药物管理局，透过使用基因组编辑改变动物基因组来开发新型动物生物技术产品的研究人员和公司将共同宣布旨在提供重要新资源的计划。 FDA 正在致力于这项倡议，作为我们不断努力推进安全有用的生物技术产品开发的一部分。

CVM中的动物生物技术产品

CVM 致力于利用科学和基于风险的法律规范来推进新技术，生产安全可靠的产品，同时保持客户信任。动物中的 IGA 和 ACTP 是 CVM 促进和支持其开发的新型动物用药品的两个例子。兽医创新计划 (VIP) 使监管流程更加清晰，加速研究和开发，并支持以有效且可预测的方式获得兽医 ACTP 和 IGA核准，以开发新动物用药品。由 CVM 设立，旨在促进

主要政府计划

  • 一个健康倡议：兽医、医学、农业、环境、林业、气象和其他学科之间的通用，以识别、预防和控制人畜共患和跨境动物疾病。为了促进跨部门合作，该部建立了海得拉巴国家卫生与人类服务研究所(NIAB) 的「同一个健康中心」。
  • 兽医生物生物製药转化研究平台 (TRPVB) 是生物製药。-清奈已建立了名为TRPVB 的合作伙伴关係。 TRPVB 的目标是在现场提供兽医疫苗、诊断和其他生物製药，并利用其优势来改善农业用地的经济状况并提高动物健康和产量。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章动物生物技术市场：副产品

  • 介绍
  • 诊断测试
  • 疫苗
  • 药物
  • 繁殖和遗传
  • 饲料添加剂

第六章动物生物技术市场：依应用分类

  • 介绍
  • 动物疾病诊断
  • 动物疾病治疗
  • 预防保健
  • 药物开发
  • 其他的

第七章动物生物技术市场：依最终用途分类

  • 介绍
  • 实验室
  • 内部检查
  • 诊所
  • 其他的

第八章动物生物技术市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Zeus Biotech Pvt. Ltd.
  • Invetx
  • Ingenta Connect
  • Kingfisher Biotech
  • Animab
  • Boehringer Ingelheim
  • Beveridge & Diamond PC
  • RSPCA
  • Santa Cruz Biotechnology
  • Pfizer
简介目录
Product Code: KSI061616206

The animal biotechnology market is estimated to grow at a CAGR of 6.28% during the forecast period.

Animals with enhanced growth rates, illness resistance, or the ability to synthesise therapeutic proteins have all been created via animal biotechnology. Animal biotechnology has advanced owing to recent advances in the sequencing of animal genomes, gene expression, and metabolic profiling of animal cells. Recent advancements in genome editing technologies, including TALENS, CRISPR-Cas, and Zinc Finger Nucleases, have opened up new possibilities for rapidly changing an animal's genetic composition to improve its health and well-being, agricultural productivity, and disease resistance.

Driving factors for the animal biotechnology market

The growing demand for genetically engineered therapeutic proteins that offer improved disease resistance, their use in the treatment of cancer, and increased preventative care for animals are a few key growth drivers for the animal biotechnology market. Rising demand for the use of animals in agriculture, meat production, and animal-based products, rising public concern for the health and welfare of animals, an expanding role for animals in the creation of human pharmaceuticals, and an increase in animal adoption are all factors that contribute to the animal biotechnology market expansion.

Increasing prevalence of obesity, inflammation and cancer in dogs

The most prevalent nutritional problem in canines is obesity, and it has become more widespread in recent years which is a major driving factor for the animal biotechnology market expansion. Obesity is prevalent in dogs in several nations. Chronic low-grade inflammation is a common explanation for why obesity has so many detrimental effects on one's health. This is generally recognised and acknowledged, and multiple research shows a link between obesity and an increased risk of developing some malignancies and associated effects. These explanations are crucial since, like obesity, dog cancer incidence has grown recently, making it a substantial cause of death for these animals.

Increasing government initiatives

To improve India's preparedness and response to potential animal pandemics in line with the One Health approach, Union Minister for Fisheries, Animal Husbandry, and Dairy, Shri Parshottam Rupala, unveiled the Animal Pandemic Preparedness Initiative and the World Bank-funded Animal Health System Support for One Health. With an emphasis on zoonotic illnesses that are dangerous to both animal and human health, this effort seeks to improve India's readiness for and response to animal pandemics. Through community engagement, this effort works to increase farmer knowledge while also enhancing veterinarian services and infrastructure, disease surveillance capabilities, early detection and response, and the ability of animal health experts. Additionally, in January 2021, through the Canadian Agricultural Partnership, the governments of Canada and Ontario are funding up to $4 million to increase farmers' access to veterinary services when they need them.

Increasing demand for vaccines

The rising prevalence of animal illnesses is the major reason for the growth of vaccines in the animal biotechnology market. Close contact with diseased people or animals, or other natural means, these illnesses are naturally passed from animals to humans because of contaminated food and water intake. Furthermore, in June 2023, the introduction of NANDI (NOC Approval for New Drug and Inoculation System) showed that DAHD is making progress towards implementing the treatments outlined in its Animal Pandemic Preparedness Initiative (APPI). Furthermore, in July 2023, the Centre on Vaccine Evaluation and Alternatives for Antimicrobials, or CVEAA, officially opened at Kansas State University's College of Veterinary Medicine to assist the use and development of animal vaccines.

In North America, it is projected that the animal biotechnology market will grow steadily.

It is projected that the existence of healthcare programmes and a rise in the number of efforts to enhance animal health will increase this region's potential for animal biotechnology market growth. Additionally, it is projected that the region's strong R&D investment would accelerate animal biotechnology market expansion in North America. For instance, in May 2023, the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration jointly announced a project that aims to provide an important new resource for researchers and businesses developing novel animal biotechnology products by using genome editing to change the animals' genomes. The FDA is working on this initiative as part of its ongoing efforts to promote the development of safe, useful biotechnology products.

Animal Biotechnology Products at CVM

CVM is dedicated to advancing new technologies for the production of safe and reliable goods while preserving customer confidence via the use of a science- and risk-based regulatory framework. IGAs in animals and ACTPs are the two examples of novel animal products that CVM promotes and supports in their development. The Veterinary Innovation Programme (VIP), which offers more clarity in the regulatory process, promotes research and development, and supports an effective and predictable pathway to approval for ACTPs and IGAs in animals, was established by CVM to facilitate advancements in the development of novel animal products.

Major Government Programs

  • One Health Initiative, the Department established a "One Health Centre" at the National Institute of Animal Biotechnology (NIAB), Hyderabad to foster cross-sectoral cooperation between the veterinary, medical, agricultural, environmental, forestry, meteorological, and other fields to identify, prevent, and control zoonoses and transboundary animal diseases.
  • Translational Research Platform for Veterinary Biologicals (TRPVB), to allow a collaborative and coordinated approach for the translation of innovations in the domain of veterinary biologicals, vaccines, and diagnostics, the Department of Biotechnology (DBT) and TANUVAS-Chennai have formed a partnership known as TRPVB. The goal of TRPVB is to translate veterinary vaccinations, diagnostics, and other biologicals into use in the field and to use their benefits to raise farmland's economic standing and increase animal health and production.

Market Key Developments

  • In June 2023, according to IDEXX Laboratories, Inc., a world leader in pet healthcare innovation the first veterinary diagnostic test for identifying kidney damage in cats and dogs was released.
  • In May 2023, Evonik introduced a new generation of Biolys®, a tried-and-true source of lysine for animal feeds. This is in keeping with the company's legacy of providing the market with cutting-edge goods and services to benefit its clients.
  • In May 2022, Animal health industry pioneer Boehringer Ingelheim announced the release of TwistPak®, a unique mixing platform. It enables swine farmers to swiftly, conveniently, and flexibly mix two vaccinations, Ingelvac CircoFLEX® and Ingelvac MycoFLEX®. TwistPak® will be offered worldwide in all certified presentation sizes.

Segmentation:

By Product

  • Diagnostic Tests
  • Vaccines
  • Drugs
  • Reproductive and Genetic Medications
  • Feed Additives

By Application

  • Diagnosis of Animal Disease
  • Treatment of Animal Disease
  • Preventive Care of Animals
  • Drug Development
  • Others

By End Use

  • Laboratories
  • In-house Testing
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ANIMAL BIOTECHNOLOGY MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Diagnostic Tests
  • 5.3. Vaccines
  • 5.4. Drugs
  • 5.5. Reproductive and Genetic
  • 5.6. Feed Additives

6. ANIMAL BIOTECHNOLOGY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diagnosis of Animal Disease
  • 6.3. Treatment of Animal Disease
  • 6.4. Preventive Care of Animals
  • 6.5. Drug Development
  • 6.6. Others

7. ANIMAL BIOTECHNOLOGY MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Laboratories
  • 7.3. In-house Testing
  • 7.4. Clinics
  • 7.5. Others

8. ANIMAL BIOTECHNOLOGY MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Zeus Biotech Pvt. Ltd.
  • 10.2. Invetx
  • 10.3. Ingenta Connect
  • 10.4. Kingfisher Biotech
  • 10.5. Animab
  • 10.6. Boehringer Ingelheim
  • 10.7. Beveridge & Diamond PC
  • 10.8. RSPCA
  • 10.9. Santa Cruz Biotechnology
  • 10.10. Pfizer